Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document 8369244
Document related concepts
no text concepts found
Transcript
TITLE: Anti-Tumor Selectivity Using Highly Efficient NQ01 Substrates INVENTORS: David Boothman TECHNOLOGY: Biologicals UTSD: 2505 SUMMARY Tumor-selectivity remains a challenge for efficacious chemotherapeutic strategies against cancer. Although the recent development of β-lapachone to specifically exploit elevated levels of NAD(P)H:quinone oxidoreductase 1 (NQO1) in most solid tumors represents a novel chemotherapeutic approach, additional compounds that kill by programmed necrosis at increased potency are needed. We show that deoxynyboquinone (DNQ), kills a wide spectrum of cancer cell types (i.e., breast, non-small-cell lung, prostate, pancreatic) in an NQO1dependent manner with greatly improved (20- to 100-fold) potency compared to β-lapachone. Thus, DNQ is a potent chemotherapeutic agent 5 exhibiting a wide therapeutic window that holds great promise for targeted therapy against a wide spectrum of difficult to treat cancers, including pancreatic and non-small cell lung. The present invention is related to compounds, compositions and methods to treat tumor cells having elevated levels of NQO1. Please contact the Office for Technology Development for more details: Phone: 214-648-1816 Email: [email protected] Please reference UT Southwestern Case Number: 2505
